At The Turning Point – Shaping The Future Of Hematology

By Heidi Cho, M.D., Vice President, Franchise Head, Hematology

Hematology development is entering a new era, driven by advances in precision medicine, cell and gene therapies and evolving regulatory expectations. Yet innovation alone is no longer enough. Success requires integrated strategies that align trial design, patient engagement, regulatory planning, operational execution and evidence generation from the outset.

This playbook explores five critical areas shaping the future of hematology development. It highlights practical strategies to help sponsors design smarter trials, navigate global regulatory complexity, reduce development risk and use real-world evidence as a strategic advantage. It also examines how data-driven feasibility, strategic site selection and accelerated study start-up can improve execution and reduce development risk. Finally, it demonstrates how real-world evidence can serve as a strategic asset, informing development decisions, supporting regulatory interactions and strengthening long-term market access.

Together, these insights provide a roadmap to help sponsors accelerate development, reduce uncertainty, make more confident decisions and deliver new therapies to patients faster.